Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. I-Mab
  6. News
  7. All News
    IMAB   US44975P1030

I-MAB

(IMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about I-MAB
10/22I MAB : to Open Translational Medicine Research Site in San Diego
MT
10/22I-MAB : Expands U.S. Footprint with New R&D Site in San Diego
PR
10/19I MAB : Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combinati..
PU
10/18I MAB : Gets IND Approval to Conduct Mid-Stage Cancer Drug Trial in China
MT
10/18I-MAB : Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combinati..
PR
10/18I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combinat..
CI
10/15I MAB : Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (T..
PU
10/13I MAB : Completes Patient Enrollment in Phase 3 Study of Multiple Myeloma Therapy
MT
10/13I-MAB : Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (T..
PR
10/13I-Mab Advances Late-Stage Development of Its Differentiated CD38 Antibody Felzartamab i..
CI
10/05I-MAB : and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at th..
PR
10/05I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at t..
CI
10/04I MAB : Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzopa..
PU
10/01I-MAB : Announces Upcoming Participation at October Conferences
PR
09/30I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzop..
CI
09/29I MAB : Exploring Partnership, Stake Sale to Major Drugmakers
MT
09/28I-Mab Secures Approval to Conduct Phase 2 Trial of Enoblituzumab Combo Therapy for Soli..
MT
09/28I-MAB : Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial..
PR
09/28I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Tria..
CI
09/20I-MAB(NASDAQGM : IMAB) added to FTSE All-World Index
CI
09/15China's biotech sector comes of age with big licensing deals, global ambitions
RE
09/13I-MAB : Added to FTSE ESG Index Series
PR
09/02I-MAB : Added to FTSE Russell Global Equity Index Series
PR
09/01I MAB : HC Wainwright Adjusts I-Mab's Price Target to $95 from $75, Keeps Buy Rating
MT
08/31I MAB : H1 Loss Widens
MT
08/31I MAB : Provides Business and Corporate Updates and Reports Financial Results for the Six ..
PU
08/31I-Mab Announces Consolidated Earnings Results for the Six Months Ended June 30, 2021
CI
08/30I-MAB : Announces Upcoming Participation at September Conferences
PR
08/27I MAB : Announces Upcoming Participation at September Conferences
PU
08/20I MAB : Announces Establishment of Environmental, Social and Governance Committee (Form 6-..
PU
08/20I-Mab Announces Committee Appointments
CI
08/19I-MAB : Announces Establishment of Environmental, Social and Governance Committee
PR
08/17I-MAB : to Provide Business and Corporate Updates and Report Financial Results for the Six..
PR
08/12I MAB : Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plon..
PU
08/11I MAB : Says Plonmarlimab Demonstrated Therapeutic Potential in Severe COVID-19
MT
08/11I-MAB : Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plon..
PR
08/11I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of Its GM-CSF Antibody Plo..
CI
08/01I-Mab Biopharma Mulls Dual-Listing on Shanghai Star Board & HKEX
CI
07/30I MAB : Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Trea..
PU
07/30I MAB : Receives FDA Approval to Begin Phase 1 Clinical Trial of Alzheimer's Drug Candidat..
MT
07/30I MAB : Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combina..
PU
07/30I-MAB : Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Trea..
PR
07/30I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Tre..
CI
07/29I MAB : Announces Authorization of a Renewed Stock Repurchase Program by the Company up to..
PU
07/29I-Mab announces an Equity Buyback for $40 million worth of its shares.
CI
07/29I-Mab authorizes a Buyback Plan.
CI
07/28SECTOR UPDATE : Health Care Stocks Adding to Mid-Week Gains Ahead of Closing Bell
MT
07/28I MAB : Cleared in China for Combo Therapy Trial of Efineptakin Alfa in Solid Tumors; Shar..
MT
07/28I-MAB : Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combina..
PR
07/28I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combin..
CI
07/27I MAB : Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of th..
PU
07/27I MAB : Secures Preliminary Board Approval to List on The Shanghai Stock Exchange's STAR M..
MT
07/27I MAB : Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of th..
PU
07/14I-Mab's Equity Buyback announced on July 15, 2020, has expired.
CI
07/13I MAB : Cantor Fitzgerald Adjusts I-Mab PT to $95 From $90, Maintains Overweight Rating
MT
07/09SECTOR UPDATE : Health Care Stocks Managing Modest Gains
MT
07/09I MAB : Signs Partnerships With Two Biotech Firms in China to Strengthen Pipeline
MT
07/09I-MAB : Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through ..
PR
07/09I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through..
CI
07/01I-MAB : Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
PR
07/01I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
CI
06/30I-MAB : Honored with Top Rankings by Institutional Investor
PR
06/29I-MAB : Announces Upcoming Participation at July Conference
PR
06/25I MAB : to Move Forward With Chinese Trial of Felzartamab in Systemic Lupus Erythematosus
MT
06/25I-MAB : Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus ..
PR
06/25I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus..
CI
06/25I MAB : Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus ..
PU
06/21I MAB : Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scie..
PU
06/21I-Mab Appoints Andrew Zhu to Its Scientific Advisory Board
CI
06/14MARKET CHATTER : I-Mab Reportedly in Talks For Cancer Drug Collaboration
MT
06/10I MAB : Cantor Fitzgerald Adjusts I-Mab's Price Target to $90 From $76, Maintains Overweig..
MT
06/07I MAB : Piper Sandler Adjusts I-Mab PT to $90 From $75, Maintains Overweight Rating
MT
06/02I-MAB : to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differen..
PR
06/02I MAB : Daiwa Securities Initiates Coverage on I-Mab With Buy Rating
MT
06/01I MAB : Appoints Ruyi He and Rong Shao to Board of Directors (Form 6-K)
PU
1  2  3Next
Upcoming event on I-MAB
10/26/21